Satellos Bioscience Inc.

Based in Toronto, Ontario, Satellos Bioscience is a clinical-stage biotechnology company focused on developing treatments for degenerative muscle diseases. The company's primary asset is SAT-3247, an oral, small-molecule drug candidate currently in development for Duchenne muscular dystrophy (DMD). The therapeutic approach is supported by the company's proprietary MyoReGenX platform, an automated microscopy system designed to replicate the muscle stem cell microenvironment outside the body, enabling drug discovery and development processes.

The company operates through research and development activities centered on its internal pipeline and collaborative arrangements. Satellos maintains license and option agreements with academic and research institutions, including the Ottawa Hospital Research Institute and the University of British Columbia, which provide access to scientific expertise and intellectual property relevant to muscle regeneration research. The company's operations span primarily Canada and Australia.

Satellos maintains a lean operational structure with 14 full-time employees as of the latest available reporting. The company is incorporated at the federal level in Canada and trades on the Nasdaq exchange. At the clinical-stage of development, the company does not yet generate product revenue and funds operations through equity capital.